GM77391/GM/NIGMS NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2007	1
2008	2
2009	2
2010	6
2011	5
2012	3
2013	4
2024	0

1

Messner MC, Cabot MC. Messner MC, et al. Adv Exp Med Biol. 2010;688:156-64. doi: 10.1007/978-1-4419-6741-1_11. Adv Exp Med Biol. 2010. PMID: 20919653 Review.

2

Ceramide-orchestrated signalling in cancer cells.

Morad SA, Cabot MC. Morad SA, et al. Nat Rev Cancer. 2013 Jan;13(1):51-65. doi: 10.1038/nrc3398. Epub 2012 Dec 13. Nat Rev Cancer. 2013. PMID: 23235911 Review.

3

Gaucher's disease and cancer: a sphingolipid perspective.

Barth BM, Shanmugavelandy SS, Tacelosky DM, Kester M, Morad SA, Cabot MC. Barth BM, et al. Crit Rev Oncog. 2013;18(3):221-34. doi: 10.1615/critrevoncog.2013005814. Crit Rev Oncog. 2013. PMID: 23510065 Free PMC article. Review.

4

Sphingolipid metabolism and drug resistance in hematological malignancies.

Gouaze-Andersson V, Cabot MC. Gouaze-Andersson V, et al. Anticancer Agents Med Chem. 2011 Nov;11(9):891-903. doi: 10.2174/187152011797655069. Anticancer Agents Med Chem. 2011. PMID: 21707483 Review.

5

Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance.

Barth BM, Gustafson SJ, Young MM, Fox TE, Shanmugavelandy SS, Kaiser JM, Cabot MC, Kester M, Kuhn TB. Barth BM, et al. Cancer Biol Ther. 2010 Dec 1;10(11):1126-36. doi: 10.4161/cbt.10.11.13438. Epub 2010 Dec 1. Cancer Biol Ther. 2010. PMID: 20935456 Free PMC article.

6

Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells.

Messner MC, Cabot MC. Messner MC, et al. Cancer Chemother Pharmacol. 2011 Aug;68(2):477-87. doi: 10.1007/s00280-010-1504-9. Epub 2010 Nov 12. Cancer Chemother Pharmacol. 2011. PMID: 21072519

7

A role for ceramide in driving cancer cell resistance to doxorubicin.

Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, Holleran WM, Giuliano AE, Jazwinski SM, Gouaze-Andersson V, Consoli DP, Cabot MC. Liu YY, et al. FASEB J. 2008 Jul;22(7):2541-51. doi: 10.1096/fj.07-092981. Epub 2008 Feb 1. FASEB J. 2008. PMID: 18245173

8

C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth.

Flowers M, Fabriás G, Delgado A, Casas J, Abad JL, Cabot MC. Flowers M, et al. Breast Cancer Res Treat. 2012 Jun;133(2):447-58. doi: 10.1007/s10549-011-1768-8. Epub 2011 Sep 21. Breast Cancer Res Treat. 2012. PMID: 21935601

9

P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.

Chapman JV, Gouazé-Andersson V, Karimi R, Messner MC, Cabot MC. Chapman JV, et al. Exp Cell Res. 2011 Jul 15;317(12):1736-45. doi: 10.1016/j.yexcr.2011.03.004. Epub 2011 Mar 21. Exp Cell Res. 2011. PMID: 21396934 Free PMC article.

10

Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.

Gouazé-Andersson V, Yu JY, Kreitenberg AJ, Bielawska A, Giuliano AE, Cabot MC. Gouazé-Andersson V, et al. Biochim Biophys Acta. 2007 Dec;1771(12):1407-17. doi: 10.1016/j.bbalip.2007.09.005. Epub 2007 Nov 9. Biochim Biophys Acta. 2007. PMID: 18035065 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year